Impacts of COX-1 gene polymorphisms on vascular outcomes in patients with ischemic stroke and treated with aspirin

Gene

Volumn 546, Issue 2, 2014, Pages 172-176

  Cao, Liping ^a   Zhang, Zhizhong ^a   Sun, Wenshan ^b,c   Bai, Wen ^b   Sun, Wen ^a   Zhang, Yumeng ^b   Wang, Xiaomeng ^b   Cai, Biyang ^b   Xie, Xia ^a   Duan, Zuowei ^a   Cai, Qiankun ^a   Liu, Dezhi ^a   Xiong, Yunyun ^a   Ma, Minmin ^a   Liu, Xinfeng ^a   Xu, Gelin ^a  

^a SOUTHERN MEDICAL UNIVERSITY   (China)

^b MEDICAL SCHOOL OF NANJING UNIVERSITY   (China)

^c THE AFFILIATED JIANGNING HOSPITAL OF NANJING MEDICAL UNIVERSITY   (China)

Author keywords

Aspirin nonresponsiveness; Prospective cohort study; Single nucleotide polymorphism

Indexed keywords

ACETYLSALICYLIC ACID; CYCLOOXYGENASE 1;

ADULT; ALLELE; ARTICLE; BRAIN HEMORRHAGE; BRAIN ISCHEMIA; CARDIOVASCULAR RISK; CAUSE OF DEATH; CHINESE; COHORT ANALYSIS; DIABETES MELLITUS; FEMALE; FOLLOW UP; GENE FREQUENCY; GENE LINKAGE DISEQUILIBRIUM; GENOTYPE; HEART INFARCTION; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; OUTCOME ASSESSMENT; PRIORITY JOURNAL; PROSPECTIVE STUDY; SINGLE NUCLEOTIDE POLYMORPHISM; TRANSIENT ISCHEMIC ATTACK; AGED; DEATH; DNA POLYMORPHISM; INCIDENCE; TREATMENT OUTCOME;

ASPIRIN NONRESPONSIVENESS; PROSPECTIVE COHORT STUDY; SINGLE NUCLEOTIDE POLYMORPHISM;

AGED; ALLELES; ASPIRIN; BRAIN ISCHEMIA; COHORT STUDIES; CYCLOOXYGENASE 1; FEMALE; GENE FREQUENCY; GENOTYPE; HUMANS; INCIDENCE; MALE; MIDDLE AGED; MYOCARDIAL INFARCTION; PLATELET AGGREGATION INHIBITORS; POLYMORPHISM, GENETIC; STROKE;

EID: 84903552204     PISSN: 03781119     EISSN: 18790038     Source Type: Journal    
DOI: 10.1016/j.gene.2014.06.023     Document Type: Article

References (21)

1. Baigent C., Blackwell L., Collins R., Emberson J., Godwin J., Peto R., et al. Aspirin in the primary and secondary prevention of vascular disease: collaborative meta-analysis of individual participant data from randomised trials. Lancet 2009, 373:1849-1860.
2. Barrett J.C., Fry B., Maller J., Daly M.J. Haploview: analysis and visualization of LD and haplotype maps. Bioinformatics 2005, 21:263-265.
3. Berger J.S., Roncaglioni M.C., Avanzini F., Pangrazzi I., Tognoni G., Brown D.L. Aspirin for the primary prevention of cardiovascular events in women and men: a sex-specific meta-analysis of randomized controlled trials. JAMA 2006, 295:306-313.
4. Chakroun T., Addad F., Yacoub S., Abderrezak F., Gerotziafas G.T., Abdelkafi S., et al. The cyclooxygenase-1 C50T polymorphism is not associated with aspirin responsiveness status in stable coronary artery disease in Tunisian patients. Genet. Test. Mol. Biomarkers 2011, 15:513-516.
5. Chen Z.J., Zhao H., He L., Shi Y., Qin Y., Shi Y., et al. Genome-wide association study identifies susceptibility loci for polycystic ovary syndrome on chromosome 2p16.3, 2p21 and 9q33.3. Nat. Genet. 2011, 43:55-59.
6. Clappers N., van Oijen M.G., Sundaresan S., Brouwer M.A., Te M.R., Keuper W., et al. The C50T polymorphism of the cyclooxygenase-1 gene and the risk of thrombotic events during low-dose therapy with acetyl salicylic acid. Thromb. Haemost. 2008, 100:70-75.
7. Fan L., Cao J., Liu L., Li X., Hu G., Hu Y., et al. Frequency, risk factors, prognosis, and genetic polymorphism of the cyclooxygenase-1 gene for aspirin resistance in elderly Chinese patients with cardiovascular disease. Gerontology 2013, 59:122-131.
8. Graeme J., Hankey J.W.E. Aspirin resistance. Lancet 2006, 367:606-617.
9. Halushka M.K., Walker L.P., Halushka P.V. Genetic variation in cyclooxygenase 1: effects on response to aspirin. Clin. Pharmacol. Ther. 2003, 73:122-130.
10. Lee C.R., Bottone F.J., Krahn J.M., Li L., Mohrenweiser H.W., Cook M.E., et al. Identification and functional characterization of polymorphisms in human cyclooxygenase-1 (PTGS1). Pharmacogenet. Genomics 2007, 17:145-160.
11. Lepantalo A., Mikkelsson J., Resendiz J.C., Viiri L., Backman J.T., Kankuri E., et al. Polymorphisms of COX-1 and GPVI associate with the antiplatelet effect of aspirin in coronary artery disease patients. Thromb. Haemost. 2006, 95:253-259.
12. Li Q., Chen B.L., Ozdemir V., Ji W., Mao Y.M., Wang L.C., et al. Frequency of genetic polymorphisms of COX1, GPIIIa and P2Y1 in a Chinese population and association with attenuated response to aspirin. Pharmacogenomics 2007, 8:577-586.
13. Li X.L., Cao J., Fan L., Wang Q., Ye L., Cui C.P., et al. Genetic polymorphisms of HO-1 and COX-1 are associated with aspirin resistance defined by light transmittance aggregation in Chinese Han patients. Clin. Appl. Thromb. Hemost. 2013, 19:513-521.
14. Liu X., Xu G., Wu W., Zhang R., Yin Q., Zhu W. Subtypes and one-year survival of first-ever stroke in Chinese patients: the Nanjing Stroke Registry. Cerebrovasc. Dis. 2006, 22:130-136.
15. Lonn E., Yusuf S., Arnold M.J., Sheridan P., Pogue J., Micks M., et al. Homocysteine lowering with folic acid and B vitamins in vascular disease. N. Engl. J. Med. 2006, 354:1567-1577.
16. Lordkipanidze M., Diodati J.G., Palisaitis D.A., Schampaert E., Turgeon J., Pharand C. Genetic determinants of response to aspirin: appraisal of 4 candidate genes. Thromb. Res. 2011, 128:47-53.
17. Maree A.O., Curtin R.J., Chubb A., Dolan C., Cox D., O'Brien J., et al. Cyclooxygenase-1 haplotype modulates platelet response to aspirin. J. Thromb. Haemost. 2005, 3:2340-2345.
18. Rist P.M., Buring J.E., Kase C.S., Kurth T. Effect of low-dose aspirin on functional outcome from cerebral vascular events in women. Stroke 2013, 44:432-436.
19. Sanderson S., Emery J., Baglin T., Kinmonth A.L. Narrative review: aspirin resistance and its clinical implications. Ann. Intern. Med. 2005, 142:370-380.
20. Ulrich C.M., Bigler J., Sibert J., Greene E.A., Sparks R., Carlson C.S., et al. Cyclooxygenase 1 (COX1) polymorphisms in African-American and Caucasian populations. Hum. Mutat. 2002, 20:409-410.
21. Wang X., Zhang Z., Liu W., Xiong Y., Sun W., Huang X., et al. Impacts and interactions of PDGFRB, MMP-3, TIMP-2, and RNF213 polymorphisms on the risk of Moyamoya disease in Han Chinese human subjects. Gene 2013, 526:437-442.